28th symposium on Medicinal Chemistry in Eastern England
28th symposium on Medicinal Chemistry in Eastern England, Thursday 27th April 2017, The Fielder Centre, Hatfield, Hertfordshire, UK
Organised by RSC-BMCS (Royal Society of Chemistry – Biological and Medicinal Chemistry Sector)
Programme
09.00 Registration, refreshments and exhibition
Session chair: Adrian Hall, UCB
09.30 Opening remarks
Nicole Hamblin, GlaxoSmithKline
09.35 From phenotypic hit to a validated target for tuberculosis
Robert Bates, GlaxoSmithKline
10.10 Discovery of potent inhibitors of the lysophospholipase autotaxin
Prit Shah, Cancer Research Technology
10.45 Refreshments and exhibition
11.15 Development of Tesirine: a clinical antibody-drug conjugate pyrrolobenzodiazepine payload: medicinal chemistry at the frontier between small molecules and biologics
Arnaud Tiberghien, Spirogen
11.50 NMR conformational analysis in molecular design – case studies and impact
Martin Packer, AstraZeneca
12.25 Highly potent cell-penetrant inhibitors of the KEAP1-NRF2 protein-protein interaction via X-ray fragment screening
Charlotte Griffiths-Jones, Astex Pharmaceuticals
13.00 Lunch and exhibition
Session Chair: Simon Ward, University of Sussex
14:05 Selective on-target chemical probes of protein-protein interactions
Alessio Ciulli, University of Dundee
14.40 Solid state studies of a preclinical candidate in a CRO environment: the importance of de-risking early
Russell Scammell, Charles River
15.15 Refreshments and exhibition
15.45 Drug discovery case study
Tom Miller, Shire
16.20 Optimisation of a series of novel smoothened inhibitors
Matilda Bingham, RedX
16.55 Concluding remarks
17.00 Close